AbbVie Inc. (ABBV) Revenue
The annual revenue for AbbVie Inc. (ABBV) is $62.82 Billion with a year-over-year growth of +9.50%. Revenue represents the total income generated from the company's primary business operations.
Annual Revenue (TTM)
$62.82B
$62.82 Billion
Year-over-Year Growth
+9.50%
vs. $56.33B prior year
Revenue CAGR
+4.59%
5 Year compound annual growth rate
Revenue CAGR (Compound Annual Growth Rate)
1 Year
+9.50%
3 Year
+3.45%
5 Year
+4.59%
10 Year
+10.20%
15 Year
+9.52%
20 Year
N/A
CAGR shows the annualized growth rate over the specified period, smoothing out year-to-year volatility.
Annual Revenue History
| Year | Revenue | YoY Change | % Change |
|---|---|---|---|
| 2025 | $61.16B | +$4.83B | +8.57% |
| 2024 | $56.33B | +$2.02B | +3.71% |
| 2023 | $54.32B | ($3.74B) | (6.44%) |
| 2022 | $58.05B | +$1.86B | +3.30% |
| 2021 | $56.20B | +$10.39B | +22.69% |
| 2020 | $45.80B | +$12.54B | +37.69% |
| 2019 | $33.27B | +$513.00M | +1.57% |
| 2018 | $32.75B | +$4.54B | +16.08% |
| 2017 | $28.22B | +$2.58B | +10.06% |
| 2016 | $25.64B | +$2.78B | +12.16% |
Revenue Growth Summary
TTM Growth
+9.50%
3-Year Avg Growth
+3.45%
5-Year Avg Growth
+4.59%
About AbbVie Inc.
AbbVie Inc. is a global biopharmaceutical company dedicated to the discovery, development, manufacturing, and commercialization of advanced medicines. Its extensive therapeutic portfolio encompasses several key areas: Immunology and Inflammation: Leading products include HUMIRA, an injectable therapy for autoimmune and intestinal Behçet's diseases; SKYRIZI, which addresses moderate to severe plaque psoriasis in adults; and RINVOQ, a JAK inhibitor for moderate to severe active rheumatoid arthritis in adult patients. Oncology and Hematology: For blood cancers, AbbVie provides IMBRUVICA and VENCLEXTA (a BCL-2 inhibitor), both indicated for adult patients with chronic lymphocytic leukemia (CLL) and small lymphocytic lymphoma (SLL). Virology: MAVYRET offers a treatment option for individuals with chronic HCV genotype 1-6 infection. Gastroenterology and Endocrinology: The company supplies CREON, an enzyme replacement therapy for exocrine pancreatic insufficiency, and Synthroid, used to manage hypothyroidism. Linzess/Constella helps treat irritable bowel syndrome with constipation (IBS-C) and chronic idiopathic constipation. Women's Health and Urology: Lupron serves as a palliative treatment for conditions like advanced prostate cancer, endometriosis, central precocious puberty, and anemia caused by uterine fibroids. ORILISSA, a nonpeptide small molecule GnRH antagonist, is designed for women experiencing moderate to severe endometriosis pain. Neurology: AbbVie offers Duopa and Duodopa, a levodopa-carbidopa intestinal gel for Parkinson's disease, and Ubrelvy to treat migraines (with or without aura) in adults. The therapeutic formulation of Botox is also part of its offerings. Ophthalmology: Its eye care segment features Lumigan/Ganfort (a bimatoprost ophthalmic solution) and Alphagan/Combigan (an alpha-adrenergic receptor agonist), both aimed at reducing elevated intraocular pressure (IOP) in patients with open-angle glaucoma (OAG) or ocular hypertension. Restasis, a calcineurin inhibitor immunosuppressant, is provided to enhance tear production, alongside other specialized eye care products. AbbVie Inc. also engages in research collaborations, including a partnership with Dragonfly Therapeutics, Inc. The company was founded in 2012 and operates from its headquarters in North Chicago, Illinois.
- Sector
- Healthcare
- Industry
- Drug Manufacturers - General
- CEO
- Robert A. Michael